Anadolu University, Faculty of Pharmacy, Department of Pharmacology, 26470 Eskişehir, Turkey.
Eur J Pharmacol. 2013 Jan 15;699(1-3):250-7. doi: 10.1016/j.ejphar.2012.10.017. Epub 2012 Oct 23.
The present study was designed to investigate the putative effect of vitexin, a flavone C-glucoside present in some drugs, medicinal plants and nutraceuticals, on the central nervous system. Vitexin (10-30 mg/kg) did not show significant alterations in the behaviour of mice tested in hole-board, plus-maze or activity cage tests. However, immobility time of the mice significantly reduced by vitexin administrations in both the tail-suspension and modified forced swimming tests. The anti-immobility effect of vitexin in the tail-suspension test was reversed with α-methyl-para-tyrosine methyl ester (AMPT, an inhibitor of catecholamine synthesis, 100mg/kg, i.p.), yohimbine (an α(2)-adrenoceptor antagonist, 1mg/kg, i.p.), NAN 190 (a 5-HT(1A) antagonist, 0.5mg/kg, i.p.), SCH 23390 (a dopamine D(1) antagonist, 0.05 mg/kg, s.c.) and sulpiride (a dopamine D(2)/D(3) antagonist, 50mg/kg, i.p.). The same effect was not reversed, however, by p-chlorophenylalanine methyl ester (PCPA; an inhibitor of serotonin synthesis 100mg/kg, i.p., administered for 4 consecutive days), ketanserin (a 5-HT(2A/2C) antagonist, 1-4 mg/kg, i.p.), ondansetron (a 5-HT(3) antagonist, 0.1-0.4 mg/kg, i.p.), prazosin (an α(1)-adrenoceptor antagonist, 1-4 mg/kg, i.p.), or propranolol (a non-selective β-adrenoceptor antagonist, 5-20mg/kg, i.p.). These results suggest that the anti-depressant-like effect of vitexin is mediated through an increase in catecholamine levels in the synaptic cleft as well as through interactions with the serotonergic 5-HT(1A), noradrenergic α(2), and dopaminergic D(1), D(2), and D(3) receptors. To our knowledge, this is the first study to show findings that indicate an anti-depressant-like effect of vitexin and its underlying mechanisms.
本研究旨在探讨牡荆素（一种存在于某些药物、药用植物和营养保健品中的黄酮 C-葡萄糖苷）对中枢神经系统的潜在作用。牡荆素（10-30mg/kg）在洞板、加迷宫或活动笼测试中未显示出对测试小鼠行为的显著改变。然而，牡荆素给药后显著减少了小鼠在悬尾和改良强迫游泳测试中的不动时间。牡荆素在悬尾试验中的抗不动作用被α-甲基-para-酪氨酸甲酯（AMPT，一种儿茶酚胺合成抑制剂，100mg/kg，ip）、育亨宾（一种α2-肾上腺素受体拮抗剂，1mg/kg，ip）、NAN 190（一种 5-HT1A 拮抗剂，0.5mg/kg，ip）、SCH 23390（一种多巴胺 D1 拮抗剂，0.05mg/kg，sc）和舒必利（一种多巴胺 D2/D3 拮抗剂，50mg/kg，ip）逆转。然而，这种作用并未被对氯苯丙氨酸甲酯（PCPA；一种 5-HT 合成抑制剂，100mg/kg，ip，连续 4 天给药）、酮色林（一种 5-HT2A/2C 拮抗剂，1-4mg/kg，ip）、昂丹司琼（一种 5-HT3 拮抗剂，0.1-0.4mg/kg，ip）、哌唑嗪（一种α1-肾上腺素受体拮抗剂，1-4mg/kg，ip）或普萘洛尔（一种非选择性β-肾上腺素受体拮抗剂，5-20mg/kg，ip）逆转。这些结果表明，牡荆素的抗抑郁样作用是通过增加突触间隙儿茶酚胺水平以及与 5-HT1A、去甲肾上腺素能α2、多巴胺能 D1、D2 和 D3 受体相互作用来介导的。据我们所知，这是第一项表明牡荆素有抗抑郁样作用及其潜在机制的研究。
